FIELD: medicine.
SUBSTANCE: the present innovation refers to the methods of selective induction, stoppage of cell growth and/or apoptosis of tumor cells and/or inhibiting histone disacetylase (HDAC) due to introducing a pharmaceutical composition that includes highly efficient HDAC inhibitors. The innovation provides unexpectedly high biological availability of active compounds in pharmaceutical compositions in case of peroral intake, where pharmaceutical compositions unexpectedly provide the chance to maintain high therapeutically efficient levels of active compounds in blood for prolonged period of time. Also, the innovation provides safe mode of daily dosing the above-mentioned pharmaceutical compositions which could be easily followed and which leads for maintaining therapeutically efficient quantity of HDAC inhibitors in vivo.
EFFECT: higher efficiency.
44 cl, 12 dwg, 5 ex, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF INDUCING TERMINAL DIFFERENTIATION | 2003 |
|
RU2394022C2 |
| METHOD OF FINAL DIFFERENTIATION INDUCTION | 2010 |
|
RU2530648C2 |
| CANCER THERAPY WITH USING HDAC INHIBITORS | 2004 |
|
RU2356547C2 |
| HYSTONE DESACETYLASE INHIBITORS FROM NOVEL BENZAMIDE DERIVATIVES WITH STRONG DIFFERENTIAL ANTI-PROLOFERATIVE ACTIVITY | 2004 |
|
RU2364589C2 |
| COMBINATION OF A HISTONE DEACETYLASE INHIBITOR AND A PROTEIN KINASE INHIBITOR AND PHARMACEUTICAL APPLICATION THEREOF | 2019 |
|
RU2770754C1 |
| COMBINATIONS OF SPECIFIC CLASS I HISTONE DEACETYLASE INHIBITORS AND PROTEASOME INHIBITORS | 2007 |
|
RU2456990C2 |
| DOSAGE FORMS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND THEIR APPLICATION | 2011 |
|
RU2609833C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI-PD-L1 ANTIBODY | 2020 |
|
RU2824577C1 |
| MACROCYCLIC COMPOUNDS, APPLIED AS HISTONE DEACETYLASE INHIBITORS | 2011 |
|
RU2565076C2 |
| PHARMACEUTICAL COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PROTEASOME INHIBITOR OR IMMUNOMODULATORY DRUG FOR TREATING BLOOD CANCER | 2017 |
|
RU2721409C1 |
